Takeda is relocating hundreds of jobs, a key Velcade patent was restored till 2022, 36 drugs were added to China's insurance drug list after huge…
After an average 44% price cuts, Chinese government will add some blockbuster foreign meds like Celgene's Revlimid to its national insurance scheme.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
A whistleblower suit against Gilead is revived, Biocon and Mylan's Herceptin biosim is delayed, and AZ is upping production to meet demands in China.
AstraZeneca is investing $77 million to expand asthma drug production at its Sydney plant, citing rising demand from China.
GlaxoSmithKline is nearing completion of its new manufacturing plant in India that will be able to crank out 8 billion tablets and 1 billion capsules a year.
Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.
Mylan and Biocon have hit a stumbling block that will delay potential approval of their biosimilar of Roche’s Herceptin in Europe.
Celgene buys Beigene’s PD-1 inhibitor, Fosun stumbles over rumors about its chairman, Neopharma expands in Japan and Abu Dhabi, and more.
It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.
UAE-based Neopharma plans to build a $100 million plant in Abu Dhabi after recently picking up a plant in Japan.